BioSpace News Archive

Products: Certain brands of diabetes drugs containing metformin Issue: Products contain or may contain a nitrosamine impurity, N-nitrosodimethylamine, above or close to the acceptable limit. What to do: You should not stop taking your metformin drug without first discussing options with your health care provider.

Persistence Market Research Released New Market Report on “Global Market Study on Insulin Delivery Devices – Asia to Witness Highest Growth by 2020” the global insulin delivery devices market is estimated at USD 9,391.1 million in 2014 and is expected to grow at a CAGR of 7% from 2014 to 2020, to reach an estimated value of USD 14,093.3 million in 2020.

According to a new market report published by Persistence Market Research “Global Market Study on Compression Therapy – Asia to Witness Highest Growth by 2020”, the global compression therapy market was valued at USD 2,377.8 million in 2014 and is expected to expand at a CAGR of 5.2% from 2014 to 2020, to reach USD 3,232.3 million by 2020.

Clearside Biomedical, Inc. (Nasdaq:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that George Lasezkay, Pharm.D., J.D., has been appointed President and Chief Executive Officer

Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, announced its full year 2019 financial results and business highlights.

Life sciences customers will gain flexibility to build bespoke, fit-for-purpose data assets and strategies to support the development and delivery of life-enhancing drugs

Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, today announced that the company will host a conference call and webcast on Monday, March 16, 2020 at 8:00 a.m. ET to report its fourth quarter 2019 financial results and other business highlights.

Arcturus Therapeutics (the “Company”, NASDAQ: ARCT), a leading messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases and vaccines, today reported its financial results for the quarter and year ended December 31, 2019, and provided a corporate update.

Burke Therapeutics, LLC, has signed an exclusive marketing and supply agreement with Coeptis Pharmaceuticals, Inc.

Biosight Ltd . today announced the raising of a $19M Series C financing. The investment is led by Israel Biotech Fund (IBF) with participation by SBI JI Innovation Fund, Arkin Bio Ventures, and additional new and existing investors.